How should I manage a patient with markedly elevated Galectin‑3 and severely reduced glomerular filtration rate (≈18 mL/min)?

Management of Elevated Galectin-3 (>30 ng/mL) with Severe CKD (GFR 18 mL/min)

With a GFR of 18 mL/min/1.73 m², you should initiate or continue SGLT2 inhibitor therapy if the patient has diabetes or albuminuria ≥200 mg/g, continue RAS inhibition (ACEi/ARB) at maximum tolerated dose unless symptomatic hypotension or uncontrolled hyperkalemia develops, and prepare for kidney replacement therapy planning given the advanced stage of kidney disease. 1

Understanding the Clinical Context

The elevated Galectin-3 level (>30 ng/mL, well above the median of ~15 ng/mL) indicates significant fibrotic activity and portends worse kidney outcomes. Research demonstrates that higher Galectin-3 independently predicts progression of kidney dysfunction 2, 3, with particularly strong associations in patients with hypertension 4. However, Galectin-3 is a prognostic biomarker, not a therapeutic target—there are no approved treatments that directly lower Galectin-3 to improve outcomes in clinical practice.

The GFR of 18 mL/min places this patient in CKD Stage G4 (severely reduced kidney function), approaching Stage G5 kidney failure (GFR <15).

Evidence-Based Treatment Algorithm

1. SGLT2 Inhibitor Therapy (First Priority)

• Initiate SGLT2i if:

  • Patient has type 2 diabetes with eGFR ≥20 mL/min 1
  • Patient has albuminuria ≥200 mg/g (≥20 mg/mmol) with eGFR ≥20 mL/min 1
  • Patient has heart failure, regardless of albuminuria level 1

• Critical consideration at GFR 18: While just below the 20 mL/min threshold for initiation, if the patient is already on an SGLT2i, continue it even as GFR falls below 20 unless intolerance or dialysis initiation occurs 1

• Galectin-3 specific evidence: Dapagliflozin showed greater absolute benefit in reducing kidney disease progression in patients with higher Galectin-3 levels (ARR 1.9% in highest quartile vs 0.6% in lowest quartile) 2, suggesting patients with elevated Galectin-3 may derive particular benefit

2. RAS Inhibition Management

• Continue ACEi or ARB at maximum approved tolerated dose even with eGFR <30 mL/min 1

• Monitor closely: Check BP, creatinine, and potassium within 2-4 weeks of any dose adjustment 1

• Discontinue or reduce dose only if:

  • Serum creatinine rises >30% within 4 weeks of initiation/dose increase 1
  • Symptomatic hypotension develops 1
  • Uncontrolled hyperkalemia despite medical management 1
  • Need to reduce uremic symptoms while treating kidney failure (eGFR <15) 1

• Hyperkalemia management: Aggressively manage elevated potassium with potassium binders, dietary restriction, or diuretic adjustment rather than stopping RASi 1

3. Nonsteroidal MRA Consideration (If Diabetic)

• Add finerenone if:

  • Type 2 diabetes present
  • eGFR >25 mL/min (this patient at 18 is below threshold) 1
  • Normal potassium concentration
  • Persistent albuminuria >30 mg/g despite maximum RASi 1

• At GFR 18, this option is NOT appropriate due to excessive hyperkalemia risk

4. Kidney Replacement Therapy Planning

With GFR 18 mL/min, immediate actions include:

• Nephrology referral if not already established
• Discuss dialysis modality options (hemodialysis vs peritoneal dialysis)
• Evaluate for kidney transplant candidacy
• Place vascular access (arteriovenous fistula) if hemodialysis anticipated—requires 3-6 months to mature
• Educate on uremic symptoms requiring urgent dialysis initiation

5. Congestion Management (If Heart Failure Present)

The elevated Galectin-3 suggests possible cardiac involvement, as it's associated with heart failure progression 3. If clinical congestion exists:

• Venous congestion is a major driver of kidney dysfunction in heart failure 5
• Target kidney perfusion pressure (MAP - CVP) >60 mmHg 5
• Loop diuretics may be needed, but recognize reduced efficacy at low GFR due to decreased distal sodium delivery 5

Common Pitfalls to Avoid

1. Don't stop RASi prematurely: The reflex to discontinue ACEi/ARB at low GFR is outdated—continue unless specific contraindications develop 1

2. Don't treat Galectin-3 as a therapeutic target: No approved therapies directly target Galectin-3 reduction in routine clinical practice. Focus on evidence-based CKD treatments

3. Don't delay KRT planning: At GFR 18, waiting for "more decline" before discussing dialysis/transplant leads to suboptimal outcomes and emergency dialysis starts

4. Don't add nonsteroidal MRA at this GFR: The eGFR >25 threshold exists for safety—hyperkalemia risk is prohibitive below this level 1

5. Don't assume SGLT2i is contraindicated: If already prescribed, continue it. If considering initiation at GFR 18-19, the decision depends on diabetes status, albuminuria, and heart failure presence—the evidence supports continuation below 20 once started 1

Monitoring Strategy

• Monthly: Creatinine, eGFR, potassium, bicarbonate
• Every 2-3 months: Urinary albumin-to-creatinine ratio, hemoglobin, calcium, phosphate, PTH
• Assess for uremic symptoms: Nausea, pruritus, altered mental status, pericarditis, volume overload refractory to diuretics

The combination of elevated Galectin-3 and GFR 18 signals high risk for progression—aggressive implementation of guideline-directed medical therapy while simultaneously preparing for kidney replacement therapy represents optimal management.